肾功能增强清除:与COVID-19相关的被低估现象
本文指出,肾功能增强清除(ARC)主要见于危重症患者,特征为肌酐清除率增高和经肾清除药物排泄加快,可能导致治疗失败。COVID-19大流行导致大量ICU入住,且有许多关于COVID-19影响肾脏的报道。本报告旨在提高临床医生对COVID-19患者中ARC及其危险因素的认识,尤其是与其他危重症的比较。
要点
- ARC主要见于危重症患者,以肌酐清除率增高和经肾清除药物清除加快为特征。
- ARC可使经肾清除药物排泄加快,患者面临治疗失败风险。
- COVID-19大流行导致大量ICU入住,有许多关于COVID-19影响肾脏的报道。
- 本报告旨在提高临床医生对COVID-19患者中ARC及其危险因素的认识,尤其是与其他危重症的比较。
适用人群与场景
- 危重症患者,尤其是COVID-19 ICU入住患者;与其他危重症患者进行比较。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「研究设计与关键结果」「证据类型、等级与局限」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Augmented renal clearance (ARC) is a phenomenon that has been described mainly in critically ill patients and is characterized by increased creatinine clearance and elimination of renally cleared medications that could place patients at risk of therapeutic failure. The COVID-19 pandemic has led to an overwhelming number of ICU admissions with many reports of the impact of COVID-19 on the kidney. This report aims to increase clinician awareness of, and risk factors for ARC in patients with COVID-19, especially in comparison to other critical illnesses.
参考来源
- Rhoney DH, Brooks AB, Nelson NR, et al. Augmented Renal Clearance: An Under-Recognized Phenomenon Associated With COVID-19. Crit Care Explor. 2022. PMID: 35141525. doi:10.1097/CCE.0000000000000617
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。